A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of Vi-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors VIVUS
- 04 Dec 2009 Planned number of patients changed from 24 to 18 as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2009 Planned end date (Jul 2009) added as reported by ClinicalTrials.gov.